Introduction {#s1}
============

During recent decades, life expectancy for the world\'s population has increased dramatically, especially for the population in the developed countries ([@B38]), when the leading causes of death shifted from infectious and acute diseases to non-communicable and chronic diseases ([@B10]). Along with population aging, the prevalence of multimorbidity as well as polypharmacy, i.e. individuals using different medications simultaneously, has increased gradually and become a global health problem ([@B33]). Individuals with multimorbidity might benefit from concurrent use of different medications to improve the quality of life and longevity. However, multiple medications may lead to the increased risk of adverse drug reactions ([@B30]) and many unexpected negative effects caused by unknown drug interactions ([@B8]) and unnecessary health expenditure ([@B21]).

A previous study based on a national representative survey in the United States showed an alarming uptrend of polypharmacy from 1999 to 2012 ([@B28]); this was consistent with another regional register-based study from the United Kingdom using data for the period between 1995 and 2010 ([@B16]). It is thus highly necessary to explore whether the uptrend of polypharmacy might be reliable based on data from nationwide registers and from countries with a national social welfare system, which could not be affected by selection and information bias. Previous studies of polypharmacy in Sweden mainly focused on elderly individuals ([@B26]; [@B18]; [@B49]; [@B40]; [@B50]), and studies included the whole population were outdated ([@B22]; [@B23]). Therefore, an updated assessment on the prevalence and temporal trend of multiple medications is highly needed. In addition, it is still largely unknown whether polypharmacy might be associated with common demographic factors, such as gender, education, and immigration status. In this study using Swedish data, we aimed to describe the temporal trend of polypharmacy using the entire Swedish population and to explore the associations of polypharmacy with gender, education, and immigration status.

Materials and Methods {#s2}
=====================

Study Population {#s2_1}
----------------

This study was approved by the Ethics Committee at Lund University, Sweden. The study population was the entire Swedish population who was alive on Jan 1st, 2006 or being born and migrated to Sweden between Jan 1st, 2006 and Dec 31st, 2014. We used the Swedish Prescribed Drug Register to evaluate multiple use of medications occurring among the entire Swedish population from 2006 to 2014. This register was created on 1st July 2005 and includes data on all prescribed drugs dispensed at pharmacies in Sweden ([@B25]; [@B24]). The rate of missing patient identity data is estimated to be lower than 0.3% ([@B51]).

In addition, we obtained sociodemographic characteristics, including age, sex, country of birth, and highest education level from Statistics Sweden\'s Total Population Register and Population Housing Census. The Swedish personal identification number, which is assigned upon birth in Sweden or, for immigrants, when registered in the Swedish population register, was used to link different registers and was then replaced with serial numbers to ensure people\'s integrity.

Outcome Measurement {#s2_2}
-------------------

We defined polypharmacy as individuals exposed to five or more drugs during a calendar month, and excessive polypharmacy as individuals exposed to 10 or more drugs in a month ([@B22]; [@B50]). As shown in [**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}, we calculated each individual\'s drug exposure during a specific calendar month using the following data: a) the date of drug dispensed; b) the defined daily doses per package; c) the number of dispensed packages. The duration of each dispensed drug was calculated by the defined daily doses per package multiplied by the number of dispensed packages. The number of different drugs used in each calendar month was retrieved according to seven-digit Anatomical Therapeutic Chemical Classification (ATC) codes.

Statistical Analysis {#s3}
====================

To make the data comparable, the rates of polypharmacy and excessive polypharmacy were age-standardized using the Swedish population distribution in 2006 as the standard population. The study population was censored at the end of the study (Dec 31st, 2014), the date of death, or the date of emigration, whichever came first. Stratified results grouped by age (\<60 years, 60--69 years, 70--79 years, 80--89 years, ≥90 years), sex, education levels, and country at birth were presented separately. Education level was classified into three groups, 0 to 9 years of schooling (elementary or compulsory education), 10 and 11 years of education (upper secondary education), and 12 years and above (higher education). Country at birth was grouped according to geographic areas: Sweden, Northern European country, Western European country, Eastern European country, Africa, Middle-Eastern country, and others. Prevalence rate ratios (PRRs) along with 95% confidence intervals (95% CIs) were calculated by dividing the prevalence rates in the study groups by that of the reference group.

We calculated the frequencies and ratios using Microsoft Excel (Office 365 MSO version 16.0). To assess the trend of polypharmacy and excessive polypharmacy during 2006--2014, we used joinpoint regression analysis which fitted a series of connected lines to the prevalence of polypharmacy and excessive polypharmacy. We joined straight-line segments at joinpoints, where the slope of prevalence trend significantly changed. If the trend of polypharmacy was a continuing straight-line without joint point, we presented it as missing. Average annual percent change (AAPC) was calculated as a geometrically weighted average of various annual percent change (APC) values from the regression analysis to describe the temporal trends of polypharmacy and excessive ([@B29]; [@B9]). This analysis was conducted using Joinpoint Statistical Software (version 4.7.0.0).

Results {#s4}
=======

[**Table 1**](#T1){ref-type="table"} shows the demographic and clinical characteristics of the study population during the study period from 2006 to 2014. The study population has increased from 9111430 in 2006 to 9747342 in 2017. Swedes accounted for 87.1% in 2006, and it was 83.5% in 2014. The top 10 drugs used in Sweden were phenoxymethylpenicillin, paracetamol, acetylsalicylic acid, diclofenac, simvastatin, omeprazole, metoprolol, furosemide, doxycycline, mucolytics.

###### 

Demographic and clinical characteristics of Swedish population from 2006 to 2014.

                               2006 (n,%)       2007 (n,%)       2008 (n,%)       2009 (n,%)       2010 (n,%)       2011 (n,%)       2012 (n,%)       2013 (n,%)       2014 (n,%)
  ---------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Overall                      9111430 (100)    9181434 (100)    9255323 (100)    9340105 (100)    9415487 (100)    9482760 (100)    9555806 (100)    9644811 (100)    9747342 (100)
  Gender                                                                                                                                                               
   Male                        4522476 (49.6)   4563049 (49.7)   4603116 (49.7)   4648716 (49.8)   4690246 (49.8)   4726808 (49.8)   4765887 (49.9)   4814338 (49.9)   4872228 (50.0)
   Female                      4588954 (50.4)   4618385 (50.3)   4652207 (50.3)   4691389 (50.2)   4725241 (50.2)   4755952 (50.2)   4789919 (50.1)   4830473 (50.1)   4875113 (50.0)
  Age group                                                                                                                                                            
   \< 60                       6925232 (76.0)   6950399 (75.7)   6980437 (75.4)   7023907 (75.2)   7064110 (75.0)   7100679 (74.9)   7143970 (74.8)   7200729 (74.7)   7272492 (74.6)
   60--69                      1037351 (11.4)   1077136 (11.7)   1111646 (12.0)   1139190 (12.2)   1161824 (12.3)   1175885 (12.4)   1179493 (12.3)   1175241 (12.2)   1161103 (11.9)
   70--79                      658603 (7.2)     662943 (7.2)     670131 (7.2)     682627 (7.3)     692650 (7.4)     707978 (7.5)     734195 (7.7)     771126 (8.0)     814338 (8.4)
   80--89                      414648 (4.6)     414029 (4.5)     415137 (4.5)     414400 (4.4)     411160 (4.4)     408208 (4.3)     406916 (4.3)     404700 (4.2)     404412 (4.1)
   90+                         75596 (0.8)      76927 (0.8)      77972 (0.8)      79981 (0.9)      85743 (0.9)      90010 (0.9)      91232 (1.0)      93015 (1.0)      94996 (1.0)
  Education, *year*                                                                                                                                                    
   0--9                        3052708 (33.5)   3130921 (34.1)   3215295 (34.7)   3307538 (35.4)   3399741 (36.1)   3489885 (36.8)   3596265 (37.6)   3743101 (38.8)   3902423 (40.0)
   10--11                      3423742 (37.6)   3408622 (37.1)   3390714 (36.6)   3372882 (36.1)   3350355 (35.6)   3327298 (35.1)   3302523 (34.6)   3269693 (33.9)   3237560 (33.2)
   12+                         2634980 (28.9)   2641891 (28.8)   2649314 (28.6)   2659685 (28.5)   2665391 (28.3)   2665577 (28.1)   2657018 (27.8)   2632017 (27.3)   2607359 (26.8)
  Birth country                                                                                                                                                        
   Sweden                      7938009 (87.1)   7955099 (86.6)   7974718 (86.2)   8002682 (85.7)   8030609 (85.3)   8055524 (84.9)   8082598 (84.6)   8111318 (84.1)   8143852 (83.5)
   Northern European country   273957 (3.0)     272629 (3.0)     269670 (2.9)     266519 (2.9)     263228 (2.8)     259748 (2.7)     256156 (2.7)     252054 (2.6)     248484 (2.5)
   Western European country    112866 (1.2)     117131 (1.3)     122625 (1.3)     126691 (1.4)     128923 (1.4)     132849 (1.4)     137052 (1.4)     141795 (1.5)     145881 (1.5)
   Eastern European country    242979 (2.7)     253645 (2.8)     263478 (2.8)     271210 (2.9)     277173 (2.9)     282846 (3.0)     288457 (3.0)     294510 (3.1)     302459 (3.1)
   African country             59401 (0.7)      65032 (0.7)      71875 (0.8)      82686 (0.9)      93283 (1.0)      100056 (1.1)     108291 (1.1)     124477 (1.3)     133224 (1.4)
   Middle-Eastern country      219967 (2.4)     237768 (2.6)     253500 (2.7)     267883 (2.9)     277860 (3.0)     287172 (3.0)     298629 (3.1)     317343 (3.3)     348217 (3.6)
   Others                      264251 (2.9)     280130 (3.1)     299457 (3.2)     322434 (3.5)     344411 (3.7)     364565 (3.8)     384623 (4.0)     403314 (4.2)     425225 (4.4)
  Comorbidity                                                                                                                                                          
   Diabetes                    240435 (2.6)     238353 (2.6)     237138 (2.6)     236554 (2.5)     237334 (2.5)     239225 (2.5)     240729 (2.5)     243127 (2.5)     248011 (2.5)
   COPD                        171402 (1.9)     169890 (1.9)     169002 (1.8)     168288 (1.8)     168037 (1.8)     167960 (1.8)     168288 (1.8)     168611 (1.7)     168987 (1.7)
   CIHD                        150720 (1.7)     154533 (1.7)     159092 (1.7)     163437 (1.7)     167926 (1.8)     172000 (1.8)     172637 (1.8)     180219 (1.9)     183622 (1.9)
  Prescription drug use                                                                                                                                                
   Phenoxymethylpenicillin     948147 (10.4)    991082 (10.8)    963254 (10.4)    889696 (9.5)     897428 (9.5)     905577 (9.5)     886665 (9.3)     789808 (8.2)     788097 (8.1)
   Paracetamol                 834350 (9.2)     857767 (9.3)     898881 (9.7)     942925 (10.1)    975973 (10.4)    999436 (10.5)    1047975 (11.0)   1096761 (11.4)   1154370 (11.8)
   Acetylsalicylic acid        691013 (7.6)     708853 (7.7)     724567 (7.8)     732815 (7.8)     731154 (7.8)     721288 (7.6)     707108 (7.4)     682098 (7.1)     680786 (7.0)
   Diclofenac                  679818 (7.5)     640122 (7.0)     660245 (7.1)     656336 (7.0)     653810 (6.9)     643328 (6.8)     559870 (5.9)     446127 (4.6)     416384 (4.3)
   Simvastatin                 490985 (5.4)     553028 (6.0)     610378 (6.6)     679019 (7.3)     701853 (7.5)     701501 (7.4)     677366 (7.1)     634840 (6.6)     632482 (6.5)
   Omeprazole                  464277 (5.1)     517365 (5.6)     569537 (6.2)     613375 (6.6)     654976 (7.0)     704698 (7.4)     729480 (7.6)     734797 (7.6)     751624 (7.7)
   Metoprolol                  434802 (4.8)     464733 (5.1)     486946 (5.3)     502354 (5.4)     517579 (5.5)     533025 (5.6)     545623 (5.7)     554950 (5.8)     558831 (5.7)
   Furosemide                  389979 (4.3)     379300 (4.1)     373847 (4.0)     363981 (3.9)     355607 (3.8)     345988 (3.6)     338335 (3.5)     330374 (3.4)     329521 (3.4)
   Doxycycline                 370012 (4.1)     387912 (4.2)     345999 (3.7)     299605 (3.2)     301999 (3.2)     330838 (3.5)     310959 (3.3)     256672 (2.7)     248519 (2.5)
   Mucolytics                  358851 (3.9)     366866 (4.0)     343667 (3.7)     339617 (3.6)     405205 (4.3)     375345 (4.0)     333598 (3.5)     318780 (3.3)     324846 (3.3)

[**Table 2**](#T2){ref-type="table"} shows the prevalence of polypharmacy and excessive polypharmacy from 2006 to 2014. The rate of polypharmacy was 16.9% in 2006; it increased to 19.0% in 2014 with a significant AAPC of 1.3. The rate of excessive polypharmacy for the same period increased from 3.8% to 5.1% with a more remarkable AAPC of 3.4.

###### 

Age-standardized rate of polypharmacy and excessive polypharmacy between 2006 and 2014.

                                         No. of individuals   Polypharmacy   Excessive polypharmacy            
  -------------------------------------- -------------------- -------------- ------------------------ -------- ------------
  2006                                   9111430              1500452        16.9                     333912   3.8
  2007                                   9181434              1570231        17.5                     356856   4.0
  2008                                   9255323              1606057        17.7                     371246   4.1
  2009                                   9340105              1634487        17.8                     380362   4.2
  2010                                   9415487              1668156        18.0                     386249   4.2
  2011                                   9482760              1693447        18.1                     390254   4.2
  2012                                   9555806              1721687        18.2                     397206   4.2
  2013                                   9644811              1803681        18.8                     440049   4.6
  2014                                   9747342              1850219        19.0                     497860   5.1
                                                                                                               
                                                              AAPC           95% CI                   AAPC     95% CI
  Average Annual Percent Change (AAPC)                        1.3            (1.0, 1.6)               3.4      (1.7, 5.1)

Rates were adjusted according to the Swedish population distribution in 2006.

In 2014, the prevalence of polypharmacy and excessive polypharmacy was 79.6 and 36.4% respectively in age group 90 and above. Compared with individuals aged 0--59 years, the PRR of polypharmacy and excessive polypharmacy among individuals aged 90 and above was 11.24 (95%CI 11.13--11.36) and 31.21 (95%CI 30.78--31.66), respectively ([**Table 3**](#T3){ref-type="table"}). The rate of polypharmacy and excessive polypharmacy in females was continuously higher than males during the study period, and the PRRs (95% CIs) were 1.20 (95% CIs 1.20--1.20) and 1.26 (95% CIs 1.25--1.26), respectively. The rate of polypharmacy and excessive polypharmacy was lowest among individuals with the highest education, and the PRRs (95% CIs) were 0.77 (0.77, 0.77) for polypharmacy and 0.66 (0.65, 0.66) for excessive polypharmacy compared with individuals with the lowest education. Immigrants from Middle-Eastern countries had the highest rates of polypharmacy and excessive polypharmacy, and the PRRs were 1.21 (95%CI 1.20--1.22) and 1.63 (95%CI 1.61--1.65) respectively compared with native Swedes. Immigrants from Western European countries had the lowest rates; a PRR of 0.80 (95%CI 0.79--0.81) for polypharmacy and 0.83 (95%CI 0.81--0.85) for excessive polypharmacy ([**Table 3**](#T3){ref-type="table"}).

###### 

Prevalence rate ratio of polypharmacy and excessive polypharmacy in 2014.

                               Polypharmacy   Excessive polypharmacy                                 
  ---------------------------- -------------- ------------------------ -------------- ------ ------- --------------
  Gender                                                                                             
   Male                        17.3           1                                       4.5    1       
   Female                      20.7           1.20                     1.20--1.20     5.7    1.26    1.25--1.26
  Age group                                                                                          
   \< 60                       8.5            1                                       1.4    1       
   60--69                      35.9           4.52                     4.50--4.54     9.2    6.99    6.93--7.05
   70--79                      54.8           7.61                     7.57--7.64     17.0   14.32   14.20--14.44
   80--89                      73.0           8.01                     7.96--8.05     29.0   19.32   19.14--19.49
   90+                         79.6           11.24                    11.13--11.36   36.4   31.21   30.78--31.66
  Education, year                                                                                    
   0--9                        21.3           1                                       6.2    1       
   10--11                      19.2           0.90                     0.90--0.90     5.2    0.82    0.82--0.83
   12+                         16.5           0.77                     0.77--0.77     4.1    0.66    0.65--0.66
  Birth country                                                                                      
   Sweden                      18.9           1                                       5.0    1       
   Northern European country   20.1           1.06                     1.05--1.07     6.0    1.19    1.17--1.21
   Western European country    15.2           0.80                     0.79--0.81     4.1    0.83    0.81--0.85
   Eastern European country    18.8           0.99                     0.99--1.00     6.0    1.21    1.19--1.22
   African country             16.8           0.89                     0.87--0.90     4.5    0.90    0.87--0.92
   Middle-Eastern country      23.0           1.21                     1.20--1.22     8.1    1.63    1.61--1.65
   Others                      16.8           0.89                     0.88--0.89     5.0    1.00    0.99--1.01

Rates were adjusted according to the Swedish population distribution in 2006.

[**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"} show the temporal trend of polypharmacy and excessive polypharmacy stratified by age group, sex, education level, and birth country respectively. The rate of polypharmacy and excessive polypharmacy increased significantly in all age groups during the study period from 2006 to 2014 ([**Tables 4**](#T4){ref-type="table"} and [**5**](#T5){ref-type="table"}).

![Age-standardized rate of polypharmacy stratified by **(A)** age group **(B)** sex **(C)** education level **(D)** birth country.](fphar-11-00326-g001){#f1}

![Age-standardized rate of excessive polypharmacy stratified by **(A)** age group **(B)** sex **(C)** education level **(D)** birth country.](fphar-11-00326-g002){#f2}

###### 

Results of joinpoint trend analysis for polypharmacy.

                               Average Annual Percent Change (AAPC) (95% CI)   Trend 1      Trend 2                        
  ---------------------------- ----------------------------------------------- ------------ ----------------- ------------ ----------------
  Overall                      1.3 (1.0, 1.6)                                  --           --                --           --
  Gender                                                                                                                   
   Male                        1.8 (1.4, 2.1)                                  --           --                --           --
   Female                      1.0 (0.7, 1.3)                                  --           --                --           --
  Age group                                                                                                                
   0--59                       2.0 (1.1, 2.9)                                  2006--2012   1.1 (0.3, 1.8)    2012--2014   4.9 (0.5, 9.4)
   60--69                      1.3 (0.9, 1.7)                                  2006--2008   2.5 (0.5, 4.5)    2008--2014   0.8 (0.5, 1.2)
   70--79                      0.9 (0.6, 1.2)                                  2006--2008   2.5 (0.9, 4.0)    2008--2014   0.3 (0.1, 0.6)
   80--89                      1.1 (0.8, 1.4)                                  2006--2008   2.1 (0.6, 3.6)    2008--2014   0.8 (0.5, 1.0)
   90+                         1.0 (0.8, 1.2)                                  --           --                --           --
  Education level, year                                                                                                    
   0--9                        1.6 (1.2, 1.9)                                  2006--2008   2.8 (1.1, 4.6)    2008--2014   1.2 (0.9, 1.5)
   10--11                      1.5 (1.2, 1.8)                                  --           --                --           --
   12+                         0.7 (0.4, 1.1)                                  --           --                --           --
  Birth country                                                                                                            
   Sweden                      1.4 (1.1, 1.7)                                  --           --                --           --
   Northern European country   1.1 (0.7, 1.4)                                  --           --                --           --
   Western European country    0.4 (0, 0.8)                                    --           --                --           --
   Eastern European country    0.6 (0.2,0.9)                                   --           --                --           --
   African country             2.0 (1.2, 2.8)                                  2006--2012   1.3 (0.6, 1.9)    2012--2014   4.3 (0.3, 8.4)
   Middle-Eastern country      1.3 (0.6, 1.9)                                  2006--2008   2.8 (−0.4, 6.1)   2008--2014   0.8 (0.2, 1.3)
   Others                      0.4 (0, 0.7)                                    --           --                --           --

###### 

Results of joinpoint trend analysis for excessive polypharmacy.

                               Average Annual Percent Change (AAPC) (95% CI)   Trend 1      Trend 2                        
  ---------------------------- ----------------------------------------------- ------------ ----------------- ------------ ------------------
  Overall                      3.4 (1.7, 5.1)                                  2006--2012   1.5 (0.1, 3.0)    2012--2014   9.2 (0.3, 18.8)
  Gender                                                                                                                   
   Male                        4.3 (2.5, 6.2)                                  2006--2012   2.2 (0.6, 3.7)    2012--2014   11.0 (1.6, 21.4)
   Female                      2.8 (1.2, 4.5)                                  2006--2012   1.2 (−0.2, 2.6)   2012--2014   8.0 (−0.6, 17.2)
  Age group                                                                                                                
   0--59                       4.4 (3.3, 5.5)                                  2006--2012   1.7 (0.9, 2.6)    2012--2014   12.7 (7.0, 18.7)
   60--69                      3.8 (2.1, 5.5)                                  2006--2012   1.9 (0.5, 3.4)    2012--2014   9.6 (0.7, 3.0)
   70--79                      2.0 (0.9, 3.2)                                  --           --                --           --
   80--89                      3.0 (1.2, 4.8)                                  2006--2012   1.2 (−0.3, 2.8)   2012--2014   8.3 (−0.9, 18.4)
   90+                         3.7 (2.8, 4.5)                                  2006--2012   1.1 (0.4, 1.8)    2012--2014   11.8 (7.4, 16.5)
  Education level, year                                                                                                    
   0--9                        4.1 (2.5, 5.8)                                  2006--2012   2.4 (1.1, 3.8)    2012--2014   9.4 (1.0, 18.5)
   10--11                      3.7 (1.9, 5.5)                                  2006--2012   1.9 (0.4, 3.4)    2012--2014   9.1 (−0.1, 19.2)
   12+                         2.5 (1.0, 4.0)                                  --           --                --           --
  Birth country                                                                                                            
   Sweden                      3.5 (1.8, 5.2)                                  2006--2012   1.5 (0.1, 3.0)    2012--2014   9.6 (0.7, 19.3)
   Northern European country   3.2 (1.7, 4.8)                                  2006--2012   1.4 (0.1, 2.8)    2012--2014   8.8 (0.7, 17.5)
   Western European country    2.2 (1.1, 3.3)                                  2006--2012   0.1 (−0.8, 1.0)   2012--2014   8.7 (3.0, 14.7)
   Eastern European country    2.2 (0.5, 3.9)                                  2006--2012   0.6 (−0.9, 2.0)   2012--2014   7.3 (−1.4,16.7)
   African country             3.7 (2.0, 5.4)                                  2006--2012   1.7 (0.3, 3.1)    2012--2014   10.0 (1.4, 19.3)
   Middle-East country         2.6 (1.8, 3.4)                                  --           --                --           --
   Others                      1.8 (0.6, 2.9)                                  --           --                --           --

Discussion {#s5}
==========

In this nationwide register-based study, a comprehensive assessment of the temporal trend in the prevalence of polypharmacy and excessive polypharmacy found that the prevalence increased gradually from 2006 to 2014. The increase was independent of gender, age, education, and immigration status, which suggests that the increased prevalence of the changes concerning polypharmacy might reflect the development of new clinical guidelines, the improved health needs of the general population, as well as the enhanced understanding of the importance of disease prevention. In addition, we found that females, individuals with a lower education, and immigrants from Middle-Eastern countries to Sweden had a higher prevalence of polypharmacy.

It should be noted that the measurement and definition of polypharmacy varied from different studies. However, our finding of an increased prevalence of polypharmacy is consistent with studies from other developed countries ([@B12]; [@B13]; [@B37]). In the National Health and Nutrition Examination Survey from the United States, the percentage of adults aged 20 and older that had polypharmacy increased remarkably from 8.2% in 1999--2000 to 15.0% in 2011--2012 and they defined polypharmacy as using five or more prescription drugs 30 days prior to the survey interview ([@B28]). A population database analysis from the United Kingdom showed that the proportion of adults that reported polypharmacy (dispensed five or more drugs) almost doubled from 11.2% in 1995 to 20.8% in 2010, and the proportion of excessive polypharmacy (dispensed 10 or more drugs) tripled from 1.7 to 5.8% ([@B16]) during this same period. A Swedish nationwide study based on data retrieved from the Swedish Prescribed Drug Register reported that the rate of individuals who were prescribed five or more drugs within a 3-month period increased from 10.2 to 11.1%, and the rate of individuals who were prescribed 10 or more drugs within a 3-month period increased from 2.1 to 2.4% ([@B23]). With the development of medical care, a growing number of chronic diseases can be treated thus resulting in an increasing number of people living with multimorbidity and taking multiple medications at the same time to treat each condition. Besides, the increased application of primary and secondary preventative strategies also improved multiple medication use ([@B35]; [@B14]). Although many interventions have been implemented to reduce polypharmacy, the results have been unsatisfactory ([@B27]; [@B46]; [@B43]; [@B41]; [@B2]).

We found that polypharmacy and excessive polypharmacy is becoming more common not only in older people but also in younger individuals. The prevalence of polypharmacy and excessive polypharmacy increased dramatically with age, peaking up to 79.6% and 36.4% in individuals aged 90 and above ([@B40]). The elderly are more likely to live with multiple chronic conditions thus leading to multiple transitions of health care and polypharmacy. Therefore, the high prevalence of multiple medication use might be associated with the relatively large number of individuals living with multimorbidity rather than due to ageing ([@B32]; [@B19]).

Our findings suggested that a higher prevalence of polypharmacy and excessive polypharmacy exists among females, which is consistent with previous studies ([@B6]; [@B47]; [@B11]; [@B39]). The possible explanation might be as follows: First, females have a life expectancy advantage over males and they have to live with chronic diseases for a longer period of time ([@B31]). Second, females may pay more attention to their health conditions and consequently are more likely to report signs and symptoms to health professionals, which often results in multiple medication use ([@B44]). In addition, women are more likely to participate in preventive health care and are more likely to be prescribed for primary and secondary prevention ([@B15]).

Individuals with a higher education level were less likely to have polypharmacy and excessive polypharmacy. Some published studies in Sweden reported similar results ([@B17]; [@B18]). Furthermore, studies from Malaysia ([@B42]) and Pakistan ([@B45]) also suggested that older patients with low level education were significantly associated with a higher rate of polypharmacy. The potential explanation might be that patients with a lower level of education are less aware of their basic health needs and expect clinicians to prescribe a greater number of medications ([@B1]). However, it could also be related to a better health in individuals with higher education and a lower need of pharmacological therapy.

We found that the age-standardized rate of polypharmacy and excessive polypharmacy were highest among immigrants from Middle-Eastern countries, and lowest among immigrants from Western European countries. Reports from Israel ([@B5]) and Turkey ([@B3]) observed a relatively high prevalence of polypharmacy, with a rate of 42.6% among Israelis aged 65 and over and 47.6% among Turks aged 60 and over, while the rate was much lower in the United Kingdom (8.7% for age group 60--69, 17.1% for age group 70--79, 24.0% for age group 80+) ([@B16]) and France ([@B20]) (21.1% for individuals aged 65 and above).

Polypharmacy is usually associated with numerous negative clinical consequences, especially in the elderly. Previous research has clearly established that the concurrent use of multiple medications may result in the increasing risk of adverse drug event both in outpatients ([@B7]) and hospitalized patients ([@B36]). Besides, individuals with polypharmacy are predisposed to drug-drug interactions, and the risk increased with the number of medications ([@B34]). The rate of non-adherence with drugs ([@B48]) as well as inappropriate prescribing ([@B4]) was also associated with polypharmacy, which may lead to consequently subsequent adverse health outcomes such as potential disease progression, treatment failure, and hospitalization. In addition, the unnecessary health expenditure caused by polypharmacy also imposes a huge financial burden on the healthcare system ([@B21]). Considering the increased risk of health problems caused by polypharmacy, clinicians should balance the benefits and potential harms when prescribing drugs against multimorbidity. The APC of polypharmacy and excessive polypharmacy was higher in 2012--2014 compared with that in 2006--2011. One possible reason was that following the Syrian Civil War in 2011 many Syrians arrived Sweden as asylum seekers. According to Statistics Sweden, 116,384 citizens of Syria (70,060 men, 46,324 women) were residing in Sweden in 2016. These immigrants from Syria might experience posttraumatic stress disorder and had a higher prevalence of polypharmacy or excessive polypharmacy. However, the joinpoint analysis was data driven may be due to spurious reasons although we did our best to identify potential drivers of the change in excessive polypharmacy. We have provided a comprehensive picture of multiple use of prescribed drugs in the entire Swedish population using individual-based exposure of dispensed drugs. The assessments of monthly exposure to polypharmacy provide more accurate information in multiple medication use status than earlier studies only using the data on prescribed date ([@B26]; [@B18]; [@B22]; [@B23]). However, there are several limitations that warrant consideration. First, the Swedish Prescribed Drug Register does not include information on over the counter medications and drugs used in hospitals, which may lead to an underestimation of the individual burden of polypharmacy. Besides, we only obtained the information about the drugs being dispensed, but we could not know whether the drugs were actually consumed or the exact date when patients start to take the medications; this may result in misclassification of polypharmacy.

In conclusion, a significant increase of polypharmacy and excessive polypharmacy was found among the Swedish population during the past decade. Individuals with older age, female sex, and lower education may have a higher rate of polypharmacy and excessive polypharmacy. The rates were highest among immigrants from Middle-Eastern countries, and lowest among immigrants from Western European countries. The causes behind this polypharmacy and the sociodemographic disparities need to be further examined.
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